AAN 2023: Neurofilament Light Chain and Disease Progression in Multiple Sclerosis

Bruce Hughes, MD, provides an overview of the use of neurofilament light chain (NfL) as a biomarker in multiple sclerosis (MS), highlighting the accuracy and reliability of plasma/serum NfL (pNfL) and cerebrospinal fluid (CSF) NfL measurements.

Bruce Hughes, MD, reviews clinical trials of use of NfL in MS, highlighting data on the Bruton’s tyrosine kinase inhibitor, evobrutinib.

An expert neurologist discusses pNfL being utilized outside of clinical trials and implemented into clinical practice for the treatment of MS.

Bruce Hughes, MD, comments on the current use and access to biomarkers in MS management, as well as sharing how NfL is being used in clinical practice presently.